EFFECT OF DEXAMETHASONE ON INTERFERON-α-INDUCED DIFFERENTIATION OF MONOCYTES TO DENDRITIC CELLS

Type I Interferons are potent inducers of monocyte’s differentiation into dendritic cells (DCs). However, sensitivity of these DCs to tolerogenic effect of glucocorticoids has not been previously investigated. The aim of this study was to investigate the effect of dexamethasone upon maturation and functions of interferonalpha-induced DCs (IFN-DC) derived from healthy donors. DCs were generated from blood monocytes cultured for 5 days with GM-CSF and IFNα, in absence or with addition of dexamethasone (10-6 M), applied on the 3rd day. Addition of dexamethasone inhibited IFN-DC maturation, which manifested with increasing numbers of CD14+ cells and decreased percentage of CD83+ DCs. Dexamethasone did not significantly influence HLA-DR, CD86 and B7H1 expression. However, it caused a 2-fold increase of tolerogenic TLR-2 molecule expression. Along with suppression of IFN-DC maturation, dexamethasone inhibited production of proinflammatory/Th1 cytokines (TNFα, IL-1, IL-2, IFNγ, IL-12), and some chemokines (MIP-1α, RANTES). Dexamethasone-treated IFN-DCs exhibited a 2-fold lower allostimulatory activity in mixed lymphocyte culture (MLC). Worth of note, the capacity of IFN-DCs to stimulate T cell proliferative response in allo-MLC showed direct correlation with CD83 expression on DCs, and an inverse correlation with CD14 and TLR-2. Evaluation of Th1/Th2-polarizing activity of IFN-DCs showed that dexamethasone exerted a pronounced inhibitory effect upon ability of DCs to stimulate T cells for IFNγ production, along with lowgrade suppressive effect upon ability of DCs to induce IL-6 production, thus being indicative for a dominance of Th2-polarizing activity of IFN-DCs under the influence of dexamethasone. In general, the data obtained show that IFN-DCs are sensitive to tolerogenic action of dexamethasone, and, hence, the IFN-DCs may mediate the immunomodulatory effect of glucocorticosteroids and represent novel candidate cells for the development of therapeutic tolerogenic DC-based vaccines applicable for management of autoimmune disorders.

dendritic cells, interferon-α, dexamethasone, allo-MLC, cytokines

1. Bakdash G., Sittig S.P., van Dijk T., Figdor C.G., de Vries I.J. The nature of activatory and tolerogenic dendritic cell-derived signal II. Front Immunol., 2013, Vol. 4, p. 53.

2. Biggioggero M., Gabbriellini L. Meroni P.L. Type I interferon therapy and its role in autoimmunity. Autoimmunity, 2010, Vol. 43, no. 3, pp. 248-254.

3. Blanco P., Palucka A.K., Gill M., Pascual V., Banchereau J. Induction of dendritic cell differentiation by IFNalpha in systemic lupus erythematosus. Science, 2001, Vol. 294, no. 5546, pp. 1540-1543.

4. Canning M.O., Grotenhuis K., de Wit H.J., Drexhage H.A. Opposing effects of dehydroepiandrosterone and dexamethasone on the generation of monocyte-derived dendritic cells. Eur. J. Endocrinol., 2000, Vol. 143, no. 5, pp. 687-695.

5. Chamorro S. TLR triggering on tolerogenic dendritic cells results in TLR2 up-regulation and a reduced proinflammatory immune program. J. Immunol., 2009, Vol. 183, no. 5, pp. 2984-2994.

6. Della Bella S., Nicola S., Riva A., Biasin M., Clerici M., Villa M.L. Functional repertoire of dendritic cells generated in granulocyte macrophage-colonystimulating factor and interferon-alpha. J. Leukoc. Biol., 2004, Vol. 75, no. 1, pp. 106-116.

7. Fukada K., Sobao Y., Tomiyama H., Oka S., Takiguchi M. Functional expression of the chemokine receptor CCR5 on virus epitope-specific memory and effector CD8+ T cells. J. Immunol., 2002, Vol. 168, no. 5, pp. 2225-2232.

8. García-González P., Morales R., Hoyos L., Maggi J., Campos J., Pesce B., Gárate D., Larrondo M., González R., Soto L., Ramos V., Tobar P., Molina M.C., Pino-Lagos K., Catalán D., Aguillón J.C. A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines. J. Transl. Med., 2013, Vol. 11, p. 128.

9. Gauzzi M.C., Maghazachi G., Belardelli F., Adorini L., Jin S.Y., Wang L., Daniel K.C., Maghazachi A.A., Belardelli F., Adorini L., Gessani S. Suppressive effect of 1a,25-Dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. J. Immunol., 2005, Vol. 174, no. 1, pp. 270-276.

10. Gessani S., Conti L., Del Cornò M., Belardelli F. Type I interferons as regulators of human antigen presenting cell functions. Toxins (Basel), 2014, Vol. 6, no. 6, pp. 1696-1723.

11. Gordon J.R., Ma Y., Churchman L., Gordon S.A., Dawicki W. Regulatory dendritic cells for immunotherapy in immunologic diseases. Front Immunol., 2014, Vol. 5, p. 7.

12. Gottenberg J.E., Chiocchia G. Dendritic cells and interferon-mediated autoimmunity. Biochimie, 2007, Vol. 89, no. 6-7, pp. 856-871.

13. Harry R.A., Anderson A.E., Isaacs J.D., Hilkens C.M. Generation and characterization of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis., 2010, Vol. 69, no. 11, pp. 2042-2050.

14. Hilkens C.M.U., Isaacs J.D. Tolerogenic dendritic cells in clinical practice. Open Arthritis Journal, 2010, Vol. 3, pp. 8-12.

15. Hubo M., Trinschek B., Kryczanowsky F., Tuettenberg A., Steinbrink K., Jonuleit H. Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. Front Immunol., 2013, Vol. 4, p. 82.

16. Leplina O.Y., Tyrinova T.V., Tikhonova M.A., Ostanin A.A., Chernykh E.R. Interferon alpha induces generation of semi-mature dendritic cells with high pro-inflammatory and cytotoxic potential. Cytokine, 2015, Vol. 71, no. 1, pp. 1-7.

17. Matasic R., Dietz A.B., Vuk-Pavlovic S. Dexamethasone inhibits dendritic cell maturation by redirecting differentiation of a subset of cells. J. Leukoc Biol., 1999, Vol. 66, no. 6, pp. 909-914.

18. Matyszak M.K., Citterio S., Rescigno M., Ricciardi-Castagnoli P. Differential effects of corticosteroids during different stages of dendritic cell maturation. Eur. J. Immunol., 2000, Vol. 30, no. 4, pp. 1233-1242.

19. Paquette R.L., Hsu N.C., Kiertscher S.M., Park A.N., Tran L., Roth M.D., Glaspy J.A. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigenpresenting cells. J. Leukoc. Biol., 1998, Vol. 64, no. 3, pp. 358-367.

20. Peña С., Gárate D., Contreras-Levicoy J., Aravena O., Catalán D., Aguillón J.C. Dexamethasone preconditioning improves the response of collagen-induced arthritis to treatment with short-term lipopolysaccharidestimulated collagen-loaded dendritic cells. Clin. Dev. Immunol., 2013, Vol. 2013, Article ID 296031.

21. Piemonti L., Monti P., Allavena P., Sironi M., Soldini L., Leone B.E., Socci C., Di Carlo V.. Glucocorticoids affect human dendritic cell differentiation and maturation. J. Immunol., 1999, Vol. 162, no. 11, pp. 6473-6481.

22. Rea D., van Kooten C., van Meijgaarden K.E., Melief C.J.M., Offringa R. Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen presenting cells that secrete IL-10. Blood, 2000, Vol. 95, no. 10, pp. 3162-3167.

23. Rönnblom L., Eloranta M.L. The interferon signature in autoimmune diseases. Curr Opin Rheumatol., 2013, Vol. 25, no. 2, pp. 248-253.

24. Rozkova D., Horvath R., Bartunkova J., Spisek R. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite up-regulation of Toll-like receptors. Clin. Immunol., 2006, Vol. 120, no. 3, pp. 260-271.

25. Santini S.M., Lapenta C., Logozzi M., Parlato S., Spada M., di Pucchio T., Belardelli F. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in hu-pbl-scid mice. J. Exp. Med., 2000, Vol. 191, no. 10, pp. 1777-1788.

26. Steinman R.M., Hawiger D., Liu K., Bonifaz L., Bonnyay D., Mahnke K., Iyoda T., Ravetch J., Dhodapkar M., Inaba K., Nussenzweig M. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci., 2003, Vol. 987, no. 1, pp. 15-25.

27. Syrbe U., Siveke J., Hamann A. Th1/Th2 subsets: distinct differences in homing and chemokine receptor expression? Springer Semin Immunopathol., 1999, Vol. 21, no. 3, pp. 263-285.

28. Thurner B., Röder C., Dieckmann D., Heuer M., Kruse M., Glaser A., Keikavoussi P., Kämpgen E., Bender A., Schuler G. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J. Immunol. Methods, 1999, Vol. 223, no. 1, pp. 1-15.

29. Unger W.W., Laban S., Kleijwegt F.S., van der Slik A.R., Roep B.O. Induction of T-reg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur. J. Immunol., 2009, Vol. 39, no. 11, pp. 3147-3159.

30. Van Kooten C., Stax A.S., Woltman A.M., Gelderman K.A. Handbook of experimental pharmacology “dendritic cells”: the use of dexamethasone in the induction of tolerogenic DCs. Handb. Exp. Pharmacol., 2009, Vol. 188, pp. 233-249.

31. Woltman A.M., de Fijter J.W., Kamerling S.W., Paul L.C., Daha M.R., van Kooten C. The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur. J. Immunol., 2000, Vol. 30, no. 7, pp. 1807-1812.

32. Woltman A.M., Vander Kooij S.W., De Fijter J.W., van Kooten C. Maturation-resistant dendritic cells induce hyporesponsiveness in alloreactive CD45RA+ and CD45RO+T-cell populations. Am. J. Transplant., 2006, Vol. 6, no. 11, pp. 2580-2591.

33. Xia C.Q., Peng R., Beato F., Clare-Salzler M.J. Dexamethasone induces IL-10-producing monocyte-derived dendritic cells with durable immaturity. Scand. J. Immunol., 2005, Vol. 62, no. 1, pp. 45-54.